These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37014667)

  • 21. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
    Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
    Tabata MM; Chase M; Kwong BY; Novoa RA; Fernandez-Pol S
    J Cutan Pathol; 2020 Nov; 47(11):1042-1045. PubMed ID: 32588467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
    Watts JM; Baer MR; Yang J; Prebet T; Lee S; Schiller GJ; Dinner SN; Pigneux A; Montesinos P; Wang ES; Seiter KP; Wei AH; De Botton S; Arnan M; Donnellan W; Schwarer AP; Récher C; Jonas BA; Ferrell PB; Marzac C; Kelly P; Sweeney J; Forsyth S; Guichard SM; Brevard J; Henrick P; Mohamed H; Cortes JE
    Lancet Haematol; 2023 Jan; 10(1):e46-e58. PubMed ID: 36370742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
    Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H
    Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia.
    Yue Z; Pan C; Wang S; N Tse A; Sheng Y
    Eur J Clin Pharmacol; 2024 Jan; 80(1):105-113. PubMed ID: 37917187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for
    Mishra A; Tamari R; DeZern AE; Byrne MT; Gooptu M; Chen YB; Deeg HJ; Sallman D; Gallacher P; Wennborg A; Hickman DK; Attar EC; Fernandez HF
    J Clin Oncol; 2022 Dec; 40(34):3985-3993. PubMed ID: 35816664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ivosidenib in Isocitrate Dehydrogenase 1
    Mellinghoff IK; Ellingson BM; Touat M; Maher E; De La Fuente MI; Holdhoff M; Cote GM; Burris H; Janku F; Young RJ; Huang R; Jiang L; Choe S; Fan B; Yen K; Lu M; Bowden C; Steelman L; Pandya SS; Cloughesy TF; Wen PY
    J Clin Oncol; 2020 Oct; 38(29):3398-3406. PubMed ID: 32530764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.
    Salhotra A; Afkhami M; Yang D; Mokhtari S; Telatar M; Gu D; Pillai RK; Weisenburger DD; Murata-Collins J; Weigel D; Aoun P; Aldoss I; Al Malki MM; Khaled S; Mei M; Ali H; Aribi A; Budde E; Sandhu K; O'Donnell M; Snyder D; Pullarkat V; Forman SJ; Marcucci G; Nakamura R; Stein A
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e400-e405. PubMed ID: 31155409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
    Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
    Ambinder A; Smith M; Tsai HL; Varadhan R; DeZern A; Dalton W; Gocke C; Webster J; Gondek L; Gojo I; Ali SA; Huff CA; Swinnen L; Wagner-Johnston N; Showel M; Prince G; Borrello I; Bolaños-Meade J; Luznik L; Jain T; Imus P; Fuchs E; Ambinder R; Gladstone DE; Levis M; Jones R; Ghiaur G; Smith BD
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):260-269. PubMed ID: 34750086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
    Reinbold R; Hvinden IC; Rabe P; Herold RA; Finch A; Wood J; Morgan M; Staudt M; Clifton IJ; Armstrong FA; McCullagh JSO; Redmond J; Bardella C; Abboud MI; Schofield CJ
    Nat Commun; 2022 Aug; 13(1):4785. PubMed ID: 35970853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study.
    Sun M; Yin Q; Liang Y; Chang C; Zheng J; Li J; Ji C; Qiu H; Li J; Gong Y; Luo S; Zhang Y; Chen R; Shen Z; Yue Z; Wang S; Shi Q; Yang J; Jin J; Wang J
    Blood Sci; 2024 Jul; 6(3):e00196. PubMed ID: 38911469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
    Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
    Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
    Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
    Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date.
    Uson Junior PLS; Borad MJ
    Cancer Manag Res; 2023; 15():1025-1031. PubMed ID: 37746315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon
    Oltvai ZN; Harley SE; Koes D; Michel S; Warlick ED; Nelson AC; Yohe S; Mroz P
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia.
    Merchant SL; Culos K; Wyatt H
    J Adv Pract Oncol; 2019 Jul; 10(5):494-500. PubMed ID: 33457062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ivosidenib and Azacitidine in IDH1-Mutated AML.
    Gil-Sierra MD; Briceño-Casado MP; Sierra-Sanchez JF
    N Engl J Med; 2022 Jun; 386(26):2535-2536. PubMed ID: 35767448
    [No Abstract]   [Full Text] [Related]  

  • 40. Ivosidenib and Azacitidine in IDH1-Mutated AML.
    Goodman AM; Mohyuddin GR; Prasad V
    N Engl J Med; 2022 Jun; 386(26):2536. PubMed ID: 35767449
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.